Relacorilant is a Small Molecule owned by Corcept Therapeutics, and is involved in 17 clinical trials, of which 9 were completed, and 8 are ongoing.

Relacorilant exhibits therapeutic intervention by acting as GR-II antagonist. Cortisol is a steroid hormone produced in response to stress and binds to GR receptor. Sustained activation of the GR receptor initiates potent anti-apoptotic signaling pathways. The drug candidate by inhibiting the receptor activity induces cancer cell apoptosis.

The revenue for Relacorilant is expected to reach a total of $4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Relacorilant NPV Report.

Relacorilant is originated and owned by Corcept Therapeutics.

Relacorilant Overview

Relacorilant (CORT-125134) is under development for the treatment of endogenous Cushing's syndrome, advanced/metastatic solid tumors such as platinum-resistant ovarian cancer, adrenocortical carcinoma, triple negative breast cancer, fallopian tube cancer, primary peritoneal cancer, metastatic castration-resistant prostate cancer. It is a small molecule administered orally. The drug candidate is a next-generation cortisol modulator that targets glucocorticoid receptor II (GR-II). It was also under development for metastatic pancreatic ductal adenocarcinoma..

Corcept Therapeutics Overview

Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder and post-traumatic stress disorder, among others. Corcept is headquartered in Menlo Park, California, the US.

The company reported revenues of (US Dollars) US$366 million for the fiscal year ended December 2021 (FY2021), an increase of 3.4% over FY2020. In FY2021, the company’s operating margin was 34%, compared to an operating margin of 36.2% in FY2020. In FY2021, the company recorded a net margin of 30.7%, compared to a net margin of 30% in FY2020. The company reported revenues of US$101.7 million for the third quarter ended September 2022, a decrease of 1.6% over the previous quarter.

Quick View – Relacorilant

Report Segments
  • Innovator
Drug Name
  • Relacorilant
Administration Pathway
  • Oral
Therapeutic Areas
  • Metabolic Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.